MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Gilead Sciences Company Profile (NASDAQ:GILD)

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 8 Hold Rating(s), 20 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $115.66 (38.78% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Leerink SwannReiterated RatingOutperform$127.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016BMO Capital MarketsReiterated RatingOutperform$97.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Jefferies GroupReiterated RatingHold$96.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016Morgan StanleyReiterated RatingHold$103.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Maxim GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Robert W. BairdReiterated RatingOutperform$135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016GabelliInitiated CoverageBuy$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Citigroup Inc.Reiterated RatingBuy$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016OppenheimerReiterated RatingBuy$120.00 -> $116.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/10/2016MizuhoReiterated RatingBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Bank of AmericaReiterated RatingNeutral$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$91.00 -> $87.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Evercore ISIReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016S&P Equity ResearchInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016BarclaysLower Price TargetOverweight$130.00 -> $115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016Needham & Company LLCReiterated RatingBuy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Wells FargoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2015ArgusReiterated RatingBuy$150.00 -> $125.39View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/10/2015Jyske BankUpgradeStrong-Buy$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2015Deutsche BankBoost Price Target$125.00 -> $135.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2015NomuraSet Price TargetBuy$141.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Edward JonesInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2014FBR & Co.Boost Price TargetOutperform$125.00 -> $130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/26/2016        
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$2.32$2.94$6.81 billion$7.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q414$2.19$2.43$6.68 million$7.31 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/23/2014Q214$1.73$2.36$5.68 billion$6.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/22/2014Q114$0.85$1.48$3.80 billion$5.00 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/23/2012$0.94$1.00ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$0.95$0.99ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$0.94$0.91ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.04$0.97ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$1.01$1.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/20/2011$0.97$0.87ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/25/2011$0.95$0.95ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$2.88$3.29$3.06
Q2 20163$2.97$3.31$3.10
Q3 20163$3.04$3.72$3.39
Q4 20162$3.53$3.87$3.70
(Data provided by Zacks Investment Research)
Dividend History for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016Tweet This Announcement  Share This Announcement on StockTwits
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015Tweet This Announcement  Share This Announcement on StockTwits
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
DateHeadline
07/01/16 04:15 AMAnalysts Shine Light on Gilead Sciences, Inc. (GILD) Following FDA Approval - Smarter Analyst
06/30/16 04:29 PMWhat Impact Will Epclusa Have On Gilead Sciences, Inc. (NASDAQ:GILD) Revenue?
06/30/16 07:02 AMGilead Sciences, Inc. (GILD) Has an Undervalued Pipeline: Leerink Partners - TCC
06/29/16 04:08 PMRevenue Estimates to see: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
06/29/16 04:08 PMGilead Sciences, Inc. (NASDAQ:GILD): Epclusa Approval Reinforces Strong Position In HCV Drug Market - Leerink ... - TCC
06/29/16 03:44 PMThe First-Ever Drug to Treat All Major Hep C Strains Just Got Approved -
06/29/16 07:00 AMHC Stocks Zone: Merck & Co., Inc. (NYSE:MRK), Gilead Sciences, Inc. (NASDAQ:GILD) - share market updates (press release)
06/29/16 07:00 AMGilead: All Eyes On FDA This Week - Seeking Alpha
06/29/16 07:00 AMGilead Sciences Inc. (GILD) Pops 5.19% for June 28 - Equities.com
06/29/16 07:00 AMHere's Why Gilead Sciences, Inc. (GILD) Stock Is up Today - Bidness ETC
06/28/16 06:38 PMGilead's Hepatitis C Drug Approved by FDA -
06/28/16 04:54 PMWhy Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today’s Best Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips The markets fared their best since the "Brexit" vote, but GILD, BAC and FB stood out the most as Tuesday's best stocks. The post Why Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today’s Best Stocks appeared first on InvestorPlace.
06/28/16 04:29 PMWhy Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today’s Best Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips The markets fared their best since the "Brexit" vote, but GILD, BAC and FB stood out the most as Tuesday's best stocks. The post Why Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today’s Best Stocks appeared first on InvestorPlace.
06/28/16 04:09 PMGilead receives approval for cheaper hepatitis C drug
06/28/16 04:09 PMU.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
06/28/16 04:09 PMGilead Sciences (GILD) Receives FDA Approval for Epclusa as HCV Treatment in All Genotypes
06/28/16 04:09 PMCompany Update (NASDAQ:GILD): Gilead wins U.S. nod for drug for all types of hepatitis C
06/28/16 03:59 PMGilead Hepatitis C Pill Approved For Broad Use, Priced Below Sovaldi -
06/28/16 03:20 PMWhy Gilead's new hepatitis C drug is a game changer — price and all - Who would have thought of a $900 tablet as a bargain? Gilead Sciences Inc. won Food and Drug Administration approval Tuesday of another groundbreaking hepatitis C treatment that is the first oral, once-a-day drug to treat all six major subtypes of the liver disease without patients taking debilitating injections of ribavirin or other drugs as well. But the cost of the drug, called Epclusa, is what's drawing the most attention. Gilead's stock (NASDAQ: GILD) was up more than 4.75 percent, or $3.75…
06/28/16 02:52 PMInstant Analysis: Gilead Sciences Wins an Important FDA Approval - Shares jump on the news that the FDA has approved the company's newest hepatitis C treatment. Could this be the start of a turnaround for Gilead's shares?
06/28/16 01:57 PMGILD Stock: FDA Greenlights Gilead Sciences, Inc. Hep-C Drug Epclusa - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (GILD) stock is up big Tuesday after the FDA granted its drug, Epclusa, approval for use in chronic HCV patients. The post GILD Stock: FDA Greenlights Gilead Sciences, Inc. Hep-C Drug Epclusa appeared first on InvestorPlace.
06/28/16 12:31 PMGilead Gets FDA Approval For Epclusa (Sofosbuvir/Velpatasvir) for All Genotypes Of Chronic Hepatitis C Treatment - Gilead Sciences, Inc. (NASDAQ: GILD) revealed Tuesday that the Food and Drug Administration has approved its Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg). According to the company, this was the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Gilead disclosed that Epclusa is also the first single tablet regimen that got approval for the treatment of patients with HCV genotype 2 and 3, without the requirement for ribavirin. The drug maker added that Epclusa for 12 weeks was ...Full story available on Benzinga.com
06/28/16 10:58 AMFDA approves first pill to treat all forms of hepatitis C - Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the combination pill from Gilead Sciences Inc. for patients...
06/27/16 02:48 PMWhen Will Gilead Sciences, Celgene, and CVS Health Hit $100 Again? - All three of stocks started the year trading for over $100, but that's no longer the case. Here's what it's going to take for each one climb back above the triple-digit threshold.
06/27/16 08:39 AMGilead Sciences, Inc. (GILD): HCV Sales To Bolster, Street Analysts Turn Bullish
06/25/16 11:09 AMCan Gilead Sciences Rebound in the Second Half of 2016? - Shares have fallen on hard times this year. Can this top biotech rebound going into the second half of 2016?
06/25/16 08:05 AMPrice Target Highlight: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
06/25/16 08:05 AMLeerink Shines Light on Gilead Sciences, Inc. (GILD) Following R&D Call With Management - Smarter Analyst
06/24/16 11:20 PM[$$] Biotech Labs Birth New Drugs—and New Fortunes - [at The Wall Street Journal] - Proprietary drugs that extend or improve the lives of millions of people have lifted stocks of the biotech companies that own them and made millionaires of many scientists and doctors behind them.
06/24/16 04:18 PMAnalysts Update on Stocks: Gilead Sciences, Inc. (NASDAQ:GILD) , Eli Lilly and Company (NYSE:LLY) - Street Updates
06/24/16 04:18 PMMost recent Analysts Rating report: Gilead Sciences, Inc. (NASDAQ:GILD) , Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Street Updates
06/24/16 04:18 PMGilead Sciences, Inc. (GILD): The Critical Support Breakdown Trading Level For This Stock - ETF Daily News
06/24/16 11:04 AMGilead Sciences (NASDAQ:GILD) Analyst Rating Consensus
06/24/16 11:04 AMGilead's (GILD) HIV Treatment Odefsey Gains Approval In EU
06/24/16 11:04 AMGilead Sciences, Inc. (NASDAQ:GILD) Secures Approval To Market Odefsey In Europe
06/23/16 03:24 PMGilead's STR Odefsey Granted EU Marketing Authorization For Treatment Of HIV
06/23/16 03:24 PMStock Update (NASDAQ:GILD): European
06/23/16 11:55 AMBig Biotech Set to Bounce Off Deep Lows (GILD, CELG) -
06/23/16 11:27 AMGilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey - Gilead Sciences, Inc. (Nasdaq: GILD) revealed the European Commission's approval for marketing authorization for the once-daily single tablet regimen (STR) Odefsey for the treatment of HIV-1 infection in some patients. According to the company, Odefsey integrates its emtricitabine and tenofovir alafenamide with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). Gilead said after the Genvoya approval in November 2015, ...Full story available on Benzinga.com
06/23/16 07:05 AM20 Companies Buying Back the Most Stock in 2016 -
06/23/16 06:54 AM7:54 am Gilead Sciences receives marketing authorization from the European Commission for Odefsey, indicated for the treatment of HIV-1 infection -
06/23/16 06:53 AMEuropean Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV - [Business Wire] - Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen Odefsey® for the treatment of HIV-1 infection in certain patients.
06/22/16 04:22 PMAnalyst Forecasts Gilead Sciences (GILD) Global Sales To Grow Over $4 Billion By 2020
06/22/16 04:22 PMGilead Sciences, Inc. (GILD): The Critical Support Breakdown Trading Level For This Stock
06/22/16 08:51 AMHC Stocks Alerts: Gilead Sciences, Inc. (NASDAQ:GILD), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - share market updates (press release)
06/22/16 07:21 AMCan These Upstarts Knock Gilead Sciences Off Its Perch? -
06/21/16 03:58 PMGilead Sciences Approaches Major Support Level
06/21/16 03:58 PMCompany Update (NASDAQ:GILD): Gilead Sciences, Inc. Presents Preliminary Data on Bictegravir - Smarter Analyst
06/21/16 03:58 PMHere's Why Leerink Reiterated Outperform on Gilead Sciences, Inc. (GILD) and GW Pharmaceuticals PLC (GWPH) - Smarter Analyst
06/21/16 10:21 AMGilead Presents Favorable Preliminary Bictegravir HIV Data -
About Gilead Sciences

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GILD
  • CUSIP: 37555810
Key Metrics:
  • Previous Close: $82.27
  • 50 Day Moving Average: $84.00
  • 200 Day Moving Average: $90.66
  • P/E Ratio: 7.12
  • P/E Growth: 10.49
  • Market Cap: $111.10B
  • Current Quarter EPS Consensus Estimate: $12.07 EPS
Additional Links:
Gilead Sciences (NASDAQ:GILD) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha